All lobbying filings

ARENTFOX SCHIFF LLP

ARENTFOX SCHIFF LLP filed a Q2 termination report for TRANSPARENCY-RX CORP. on October 19, 2026, reporting $20,000 in lobbying income.

Lobbying for TRANSPARENCY-RX CORP. · Coalition of licensed transparent pharmacy benefit managers

All filings by ARENTFOX SCHIFF LLP · Everything TRANSPARENCY-RX CORP. has reported

Filing · LD-2 quarterly report Q2 termination

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Oct 19, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

Virginia

Representation ended

Jun 14, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Pharmacy Benefit Manager reform Transparency in prescription drug markets Prescription drug prices H.R.7148 (Consolidated Appropriations Act, 2026), regarding Pharmacy Benefit Manager reform, transparency in prescription drug markets, and prescription drug prices H.R. 6609 and H.R. 6610 (Pharmacists Fight Back Act), generally H.R. 5582 and S. 2355 (Patients Deserve Price Tags Act), generally

Bills named in this filing 5

H.R. 7148
Consolidated Appropriations Act, 2026
H.R. 6609
Pharmacists Fight Back in Medicare and Medicaid Act
H.R. 6610
Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
H.R. 5582
Patients Deserve Price Tags Act
S. 2355
Patients Deserve Price Tags Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.